Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 62Tumor-Agnostic 2NET 1Endocrine 1Dermatologic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × folfirinox × Tumor-Agnostic × Clear all
NCT02178709 2022-04-19

A Phase II Study of Neoadjuvant FOLFIRINOX

Indiana University

Phase 2 Completed
48 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT04398927 2021-02-04

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Sun Yat-sen University

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡